Author/Authors :
Aryanpour، Roya نويسنده , , Parizadeh، Seyed Mohammad Reza نويسنده Mashhad University of Medical Sciences , , Moohebati، Mohsen نويسنده Mashhad University of Medical Sciences , , Tavallaie، Shima نويسنده Mashhad University of Medical Sciences , , Sahebkar، Amirhossein نويسنده Mashhad University of Medical Sciences , , Mohammadi ، Shabnam نويسنده Department of Anatomy, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. , , Ghayour-Mobarhan، Majid نويسنده MD, PhD, Cardiovascular Research Center, Avicenna (Bu-Ali) Research Institute, Mashhad University of Medical Science, Mashhad , , Ferns، Gordon AA. نويسنده University of Brighton, BN1 9PH, United Kingdom ,
Abstract :
Background: Increased heat shock protein (Hsp) expression is associated with
atherogenesis. The statin group of cholesterol lowering drugs reduces cardiovascular
events and this may be related to their pleiotropic effects that may include their antiinflammatory
properties. The aim of this study was to evaluate the effect of 40 mg
simvastatin on serum levels of Hsp-60 and -70 in dyslipidemic individuals. Methods:
Patients (n=102) were treated with simvastatin (40mg/day), or placebo in a
randomized, double-blind, placebo-controlled, cross-over trial. Lipid profile and
serum Hsp-60 and -70 antigen levels were measured before and after each treatment
period. Seventy-seven subjects completed the study. Data were analyzed using
Independent-Samples t-test for parametric data and Mann–Whitney test for nonparametric
data and chi-square test for categorical data. Results: There was a
reduction in the level of LDL-C (p < 0.001), total cholesterol (p < 0.001), and
triglycerides (p < 0.05). However, simvastatin therapy did not significantly alter the
serum level of HDL-C, Hsp-60 and -70 (p > 0.05). Conclusions: We found that statin
therapy did not significantly affect the serum level of HSP-60 and -70.
